CN111494237A - Soluble micro-needle patch - Google Patents
Soluble micro-needle patch Download PDFInfo
- Publication number
- CN111494237A CN111494237A CN202010367191.0A CN202010367191A CN111494237A CN 111494237 A CN111494237 A CN 111494237A CN 202010367191 A CN202010367191 A CN 202010367191A CN 111494237 A CN111494237 A CN 111494237A
- Authority
- CN
- China
- Prior art keywords
- parts
- needle body
- soluble
- raw material
- patch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002994 raw material Substances 0.000 claims abstract description 36
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 33
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 33
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 32
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 29
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960003471 retinol Drugs 0.000 claims abstract description 16
- 235000020944 retinol Nutrition 0.000 claims abstract description 16
- 239000011607 retinol Substances 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 108010076876 Keratins Proteins 0.000 claims abstract description 9
- 102000011782 Keratins Human genes 0.000 claims abstract description 9
- KVTFEOAKFFQCCX-UHFFFAOYSA-N N-hexadecanoylglycine Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(O)=O KVTFEOAKFFQCCX-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940075639 palmitoyl glycine Drugs 0.000 claims abstract description 9
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 7
- 206010000496 acne Diseases 0.000 claims abstract description 7
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 6
- 230000002087 whitening effect Effects 0.000 claims abstract description 5
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 4
- HRGUSFBJBOKSML-UHFFFAOYSA-N 3',5'-di-O-methyltricetin Chemical compound COC1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 HRGUSFBJBOKSML-UHFFFAOYSA-N 0.000 claims abstract description 3
- IDDMFNIRSJVBHE-UHFFFAOYSA-N Piscigenin Natural products COC1=C(O)C(OC)=CC(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)=C1 IDDMFNIRSJVBHE-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 3
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 3
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 3
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 claims abstract description 3
- BMCJATLPEJCACU-UHFFFAOYSA-N tricin Natural products COc1cc(OC)c(O)c(c1)C2=CC(=O)c3c(O)cc(O)cc3O2 BMCJATLPEJCACU-UHFFFAOYSA-N 0.000 claims abstract description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 22
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims description 16
- 238000004132 cross linking Methods 0.000 claims description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 14
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 14
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 14
- 229960000401 tranexamic acid Drugs 0.000 claims description 14
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 11
- 229930003268 Vitamin C Natural products 0.000 claims description 11
- 235000019154 vitamin C Nutrition 0.000 claims description 11
- 239000011718 vitamin C Substances 0.000 claims description 11
- 229960000271 arbutin Drugs 0.000 claims description 8
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 7
- 108010035532 Collagen Proteins 0.000 claims description 7
- 229930003427 Vitamin E Natural products 0.000 claims description 7
- 229920001436 collagen Polymers 0.000 claims description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 229960004889 salicylic acid Drugs 0.000 claims description 7
- 235000019165 vitamin E Nutrition 0.000 claims description 7
- 229940046009 vitamin E Drugs 0.000 claims description 7
- 239000011709 vitamin E Substances 0.000 claims description 7
- OQILSTRGJVCFAG-UHFFFAOYSA-N 1-(oxiran-2-ylmethoxy)butan-1-ol Chemical compound CCCC(O)OCC1CO1 OQILSTRGJVCFAG-UHFFFAOYSA-N 0.000 claims description 6
- 108010024636 Glutathione Proteins 0.000 claims description 6
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims description 6
- 229960003180 glutathione Drugs 0.000 claims description 6
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims description 6
- 229960004023 minocycline Drugs 0.000 claims description 6
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 5
- 238000010494 dissociation reaction Methods 0.000 claims description 5
- 230000005593 dissociations Effects 0.000 claims description 5
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 3
- 235000011477 liquorice Nutrition 0.000 claims description 3
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 claims 1
- 235000005291 Rumex acetosa Nutrition 0.000 claims 1
- 240000007001 Rumex acetosella Species 0.000 claims 1
- 235000003513 sheep sorrel Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 230000001815 facial effect Effects 0.000 abstract description 6
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 25
- 239000000047 product Substances 0.000 description 13
- 230000003796 beauty Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 108010022355 Fibroins Proteins 0.000 description 6
- 206010014970 Ephelides Diseases 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 4
- 229940093767 glabridin Drugs 0.000 description 4
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 4
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 4
- 230000000475 sunscreen effect Effects 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- 208000020154 Acnes Diseases 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- ROTFCACGLKOUGI-JYJNAYRXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-(3-acetamidopropanoylamino)-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](NC(=O)CCNC(=O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ROTFCACGLKOUGI-JYJNAYRXSA-N 0.000 description 1
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 1
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- VNXWANZMRATDQM-UHFFFAOYSA-N 2-(2-phenylethyl)benzene-1,3-diol Chemical compound OC1=CC=CC(O)=C1CCC1=CC=CC=C1 VNXWANZMRATDQM-UHFFFAOYSA-N 0.000 description 1
- IDUUXROOZBOOPH-QHHAFSJGSA-N 2-{[(2E)-3-(3,4-dihydroxyphenyl)-1-hydroxyprop-2-en-1-ylidene]amino}-5-hydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1NC(=O)\C=C\C1=CC=C(O)C(O)=C1 IDUUXROOZBOOPH-QHHAFSJGSA-N 0.000 description 1
- 241000428811 Alternanthera Species 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 229930190481 Avenanthramide Natural products 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 244000146462 Centella asiatica Species 0.000 description 1
- 235000004032 Centella asiatica Nutrition 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 241001673966 Magnolia officinalis Species 0.000 description 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 240000003793 Rhizophora mangle Species 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 1
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 description 1
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 229940093497 ergothioneine Drugs 0.000 description 1
- 229940011399 escin Drugs 0.000 description 1
- 229930186222 escin Natural products 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229940084038 salix alba bark extract Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
Abstract
The invention provides a soluble microneedle patch, which comprises a patch and a soluble needle body arranged on the front surface of the patch, wherein the soluble needle body is of a segmented structure, the tail section of the needle body close to the patch is prepared from the following raw material A in parts by weight, and the first section of the needle body far away from the patch is prepared from the following raw material B in parts by weight; the raw material A comprises: 20-40 parts of sodium hyaluronate A with the molecular weight of 5-20 ten thousand, 10-15 parts of a viscous mixture, 22-35 parts of palmitoyl glycine, 10-50 parts of keratin, 15-18 parts of retinol and 11-13 parts of tricin; the raw material B comprises: 50-80 parts of 120-sodium hyaluronate B with the molecular weight of 130 ten thousand, 13-16 parts of whitening component, 7-15 parts of antiallergic component, 18-22 parts of antioxidant component, 8-12 parts of anti-aging component and 4-7 parts of acne-removing component. The soluble microneedle patch has long lasting period, can obviously repair facial pockmarks, integrates various skin care effects and has good beautifying effect.
Description
Technical Field
The invention relates to a microneedle cosmetic product, in particular to a soluble microneedle patch.
Background
The soluble micro-needle patch is prepared by preparing nano-scale fine micro-needles from hyaluronic acid which is a component existing in the skin, and various active components (such as components for removing wrinkles, whitening or stimulating hair growth) can be added into the micro-needles. When in use, the hyaluronic acid and other effective components are directly injected into the dermis layer of the skin through the tiny micro-needles, so that the hyaluronic acid and other effective components are completely absorbed and dissolved by the skin, and various problems of the skin are effectively improved.
Currently, soluble microneedle technology has been rapidly developed. As patent document CN209316551U, there is provided a dissolvable microneedle patch comprising: a dissolvable substrate and a dissolvable microneedle array, and a viscous mixture having solubility and/or biodegradability for adhering the dissolvable microneedle patch to a skin surface; wherein the dissolvable substrate comprises an inner surface facing the skin, and an outer surface facing away from the skin; the dissolvable microneedle array and the viscous mixture are both disposed on an inner surface of the dissolvable substrate. For example, patent document CN105030657A provides an implantable multifunctional composite fibroin microneedle array, which at least comprises a substrate and fibroin microneedles distributed on the surface of the substrate, wherein the fibroin microneedles are conical or similar to conical, the diameter of the bottom of the fibroin microneedle is 50 μm-1 cm, the length of the fibroin microneedle is 50 μm-5 cm, the diameter of the tip is not more than 50 μm, and the distance between the fibroin microneedles is 0.1 mm-5 cm.
Further, patent document CN204890943U provides a multi-segment microneedle array, which is an array of microneedles that are perpendicular to a substrate and uniformly arranged; the micro-needle comprises a drug-loaded tip and a non-drug-loaded base; the tip of the drug-carrying tip is upward, a drug-free base is arranged below the drug-carrying tip, and the lower part of the drug-free base is fixed on the substrate; the non-drug-carrying base is of a convex structure and penetrates into the bottom of the drug-carrying tip upwards; the medicine carrying tip is one section or several sections are vertically overlapped. This multistage formula micropin array is because its medicine carrying point-end has sufficient hardness, can effectively pierce through the stratum corneum on skin top layer, its not carry the medicine geometrical connection structure between base and the medicine carrying point-end can send into the medicine carrying point-end completely and make the abundant transmission of subcutaneous medicine, has improved the drug-carrying capacity greatly and has dosed efficiency to thereby can realize carrying medicine section and needle body quickly separating reduces micropin operating time, provides convenience for the object of dosing of difficult control such as animal or children. Patent document CN107050635A provides a segmented soluble microneedle, which comprises a needle body made of soluble polymer, wherein the needle body at least comprises a needle base part and a needle tip part, and only the needle tip part of the whole needle body is embedded with an effective medicinal component; the height of the needle base part is larger than the thickness of the epidermis layer, so that the needle base part can penetrate through the epidermis layer and can not release the effective pharmaceutical ingredients at the epidermis layer; the distance from the top end of the needle tip to the bottom surface of the needle base is greater than the distance from the dermis layer to the outer surface of the epidermis layer, so that the needle tip can enter the dermis layer to release the active pharmaceutical ingredient in the dermis layer.
As described above, the existing integrated soluble microneedles and multi-segment microneedles have mature processes in terms of manufacturing technology and effective/functional component carrying, and have good cosmetic effects in the early stage of microneedle beauty, however, most of the available soluble microneedles in the market have unsatisfactory problems in the middle and later stages of beauty, such as the problem of slight local depression of skin in the middle and later stages after microneedle beauty, especially the microneedle beauty is performed again after 2-3 months, otherwise, the skin is prone to lose elasticity and luster.
Disclosure of Invention
The invention aims to provide a soluble microneedle patch to prolong the lasting period of microneedle beauty.
In order to achieve the above object, the present invention adopts the following technical solutions.
A soluble microneedle patch comprises a patch and a soluble needle body arranged on the front surface of the patch, wherein the soluble needle body is of a segmented structure, the tail section of the needle body close to the patch is prepared from the following raw material A in parts by weight, and the first section of the needle body far away from the patch is prepared from the following raw material B in parts by weight; the raw material A comprises: 20-40 parts of 5-20 ten thousand molecular weight sodium hyaluronate A, 10-15 parts of a viscous mixture, 22-35 parts of palmitoyl glycine, 10-50 parts of keratin, 15-18 parts of retinol and 11-13 parts of tricin, wherein the sodium hyaluronate A is a product crosslinked by divinyl sulfone, and the crosslinking dissociation ratio of the sodium hyaluronate A is 71% to 29%; the raw material B comprises: 50-80 parts of 120-sodium hyaluronate B with the molecular weight of 130 ten thousand, 13-16 parts of whitening component, 7-15 parts of antiallergic component, 18-22 parts of antioxidant component, 8-12 parts of anti-aging component and 4-7 parts of acne-removing component, wherein the sodium hyaluronate B is a product crosslinked by butanediol glycidyl ether, and the crosslinking dissociation ratio is 84% to 16%.
Furthermore, the soluble needle body is of a two-section structure, and the length of the tail section needle body is 1/4-1/3 of the total length of the soluble needle body.
Furthermore, the first segment of the soluble needle body is connected with the tail segment of the soluble needle body in an embedded mode.
Further, the raw material a further comprises: 7-8 parts of tranexamic acid, 5-7 parts of vitamin C, 5-7 parts of vitamin E, 6-9 parts of arbutin and 10-12 parts of Glassy liquorice.
Further, the raw material B further includes: 14-17 parts of polyvinylpyrrolidone and 4-9 parts of collagen.
Preferably, the raw material A consists of 28-30 parts of sodium hyaluronate A with the molecular weight of 5-20 ten thousand, 12 parts of viscous mixture, 25 parts of palmitoyl glycine, 30 parts of keratin, 15 parts of retinol, 11 parts of minocycline, 7 parts of tranexamic acid, 6 parts of vitamin C, 6 parts of vitamin E, 8 parts of arbutin and 11 parts of Glassy liquorice; the raw material B comprises 120-130 ten thousand molecular weight sodium hyaluronate B65 parts, tranexamic acid 15 parts, nicotinamide 13 parts, glutathione 21 parts, retinol 10 parts, salicylic acid 6 parts, vitamin C6 parts, polyvinylpyrrolidone 14 parts and collagen 7 parts.
By adopting the soluble microneedle patch provided by the invention, the facial beauty duration of a user is more than half a year, and the problem of local skin concavity is hardly caused in the middle and later stages of microneedle beauty.
The soluble microneedle sticker provided by the invention can obviously repair pocks on the face, can repair pocks on the face with one time by using the soluble microneedle sticker, can obviously improve pocks on the face with larger size by using the soluble microneedle sticker with one time, and can repair pocks on the face with two times by using the soluble microneedle sticker.
The soluble microneedle patch provided by the invention has multiple skin care effects, is good in beautifying effect, can enable skin to be more elastic and glossy, can prevent skin moisture loss, moisturize and preserve water, can also whiten skin, resist oxidation and aging, resist sunscreen, allergy and wrinkle, has an acne generation prevention effect, and particularly has remarkable effects on removing freckles and acnes and improving facial melanin deposition.
By adopting the soluble microneedle patch provided by the invention, the sunscreen and antiallergic effects can be achieved without other sunscreen creams or antiallergic creams within the period of validity of the microneedle beauty.
Drawings
Fig. 1 is a schematic view of a dissolvable microneedle patch according to the present invention;
fig. 2 is an enlarged partial cross-sectional view of a dissolvable microneedle patch according to the present invention;
FIG. 3 is a first comparison of a dissolvable microneedle patch of the present invention before and after use, with the left portion of the figure before use and the right portion of the figure before use;
FIG. 4 is a second comparison of soluble microneedles before and after application of the invention, the left panel being before use and the right panel being before use;
fig. 5 is a third comparison of soluble microneedles before and after application of the present invention, the left part of the figure being before application and the right part of the figure being before application;
fig. 6 is a comparison graph of 8 months after the soluble microneedle patch of the present invention is applied and the conventional soluble microneedle is applied, the left part of the graph is the graph after the conventional soluble microneedle is applied, the right part of the graph is the graph after the soluble microneedle patch of the present invention is applied, and the dark gray and black areas in the graph show that the skin is partially recessed;
fig. 7 is a fourth comparative image before and after application of the dissolvable microneedles of the present invention, the left image being a schematic image before use and the right image being a schematic image after 3 months of use.
Detailed Description
The present invention will be further described with reference to the following examples, which are provided only for the understanding of the principle and the core idea of the present invention, and are not intended to limit the scope of the present invention. It is pointed out that the following examples are not to be construed as limiting the scope of the invention, and that those skilled in the art will be able to make numerous insubstantial modifications and adaptations in view of the teachings of the present invention.
Example 1
A soluble micro-needle patch is shown in figure 1 and comprises a patch 1 and a soluble needle body arranged on the front surface of the patch 1, wherein the soluble needle body is of a two-section structure, the total length of the soluble needle body is 1300 mu m, the length of a tail section needle body 2 is 1/4 of the total length of the soluble needle body, and a first section needle body 3 of the soluble needle body and the tail section needle body 2 are mutually embedded and connected.
In the embodiment, the tail section needle body 2 close to the patch 1 is prepared from the following raw material A in parts by weight, and the first section needle body 3 far away from the patch 1 is prepared from the following raw material B in parts by weight; specifically, the raw material A comprises 30 parts of 5-20 ten thousand molecular weight sodium hyaluronate A, 12 parts of a viscous mixture (the viscous mixture is a pure natural extract of palm oil and monooleate according to a weight ratio =1: 1), 25 parts of palmitoyl glycine, 30 parts of keratin, 15 parts of retinol, 11 parts of minocycline, 7 parts of tranexamic acid, 6 parts of vitamin C, 6 parts of vitamin E, 8 parts of arbutin and 11 parts of glabridin, wherein the sodium hyaluronate A is a product subjected to divinyl sulfone crosslinking, and the crosslinking free ratio is 71% -29%; the raw material B comprises 65 parts of 120-130 ten million molecular weight sodium hyaluronate B, 15 parts of tranexamic acid, 13 parts of nicotinamide, 21 parts of glutathione, 10 parts of retinol, 6 parts of salicylic acid, 6 parts of vitamin C, 14 parts of polyvinylpyrrolidone and 4 parts of collagen, wherein the sodium hyaluronate B is a product crosslinked by butanediol glycidyl ether, and the crosslinking free ratio is 84% to 16%.
Example 2
A soluble micro-needle patch is shown in figure 1 and comprises a patch 1 and a soluble needle body arranged on the front surface of the patch 1, wherein the soluble needle body is of a two-section structure, the total length of the soluble needle body is 1200 mu m, the length of a tail section needle body 2 is 1/3 of the total length of the soluble needle body, and a first section needle body 3 of the soluble needle body and the tail section needle body 2 are mutually embedded and connected.
In the embodiment, the tail section needle body 2 close to the patch 1 is prepared from the following raw material A in parts by weight, and the first section needle body 3 far away from the patch 1 is prepared from the following raw material B in parts by weight; specifically, the raw material A comprises 28 parts of 5-20 ten thousand molecular weight sodium hyaluronate A, 10 parts of a viscous mixture (the viscous mixture is a pure natural extract of palm oil), 22 parts of palmitoyl glycine, 12 parts of keratin, 15 parts of retinol, 13 parts of minocycline, 8 parts of tranexamic acid, 6 parts of vitamin C, 7 parts of vitamin E, 6 parts of arbutin and 10 parts of glabridin, wherein the sodium hyaluronate A is a product subjected to divinyl sulfone crosslinking, and the crosslinking free ratio is 71%: 29%; the raw material B comprises 50 parts of 120-130 ten million molecular weight sodium hyaluronate B, 13 parts of tranexamic acid, 7 parts of nicotinamide, 18 parts of glutathione, 10 parts of retinol, 5 parts of salicylic acid, 5 parts of vitamin C, 16 parts of polyvinylpyrrolidone and 4 parts of collagen, wherein the sodium hyaluronate B is a product crosslinked by butanediol glycidyl ether, and the crosslinking free ratio is 84% to 16%.
Example 3
A soluble micro-needle patch is shown in figure 1 and comprises a patch 1 and a soluble needle body arranged on the front surface of the patch 1, wherein the soluble needle body is of a two-section structure, the total length of the soluble needle body is 1350 mu m, the length of a tail section needle body 2 is 2/7 of the total length of the soluble needle body, and a first section needle body 3 of the soluble needle body and the tail section needle body 2 are mutually embedded and connected.
In the embodiment, the tail section needle body 2 close to the patch 1 is prepared from the following raw material A in parts by weight, and the first section needle body 3 far away from the patch 1 is prepared from the following raw material B in parts by weight; specifically, the raw material A comprises 35 parts of 5-20 ten thousand molecular weight sodium hyaluronate A, 15 parts of a viscous mixture (the viscous mixture is a pure natural extract of monooleate), 35 parts of palmitoyl glycine, 40 parts of keratin, 18 parts of retinol, 12 parts of minocycline, 7 parts of tranexamic acid, 7 parts of vitamin C, 7 parts of vitamin E, 9 parts of arbutin and 12 parts of glabridin, wherein the sodium hyaluronate A is a product subjected to divinyl sulfone crosslinking, and the crosslinking free ratio is 71%: 29%; the raw material B comprises 50 parts of 120-130 ten million molecular weight sodium hyaluronate B, 16 parts of tranexamic acid, 15 parts of nicotinamide, 19 parts of glutathione, 12 parts of retinol, 6 parts of salicylic acid, 6 parts of vitamin C, 17 parts of polyvinylpyrrolidone and 9 parts of collagen, wherein the sodium hyaluronate B is a product crosslinked by butanediol glycidyl ether, and the crosslinking free ratio is 84% to 16%.
Example 4
A soluble micro-needle patch is shown in figure 1 and comprises a patch 1 and a soluble needle body arranged on the front surface of the patch 1, wherein the soluble needle body is of a two-section structure, the total length of the soluble needle body is 1350 mu m, the length of a tail section needle body 2 is 1/4 of the total length of the soluble needle body, and a first section needle body 3 of the soluble needle body and the tail section needle body 2 are mutually embedded and connected.
In the embodiment, the tail section needle body 2 close to the patch 1 is prepared from the following raw material A in parts by weight, and the first section needle body 3 far away from the patch 1 is prepared from the following raw material B in parts by weight; specifically, the raw material A comprises 40 parts of sodium hyaluronate A with the molecular weight of 5-20 ten thousand, 12 parts of a viscous mixture, 33 parts of palmitoyl glycine, 38 parts of keratin, 13 parts of retinol, 13 parts of minocycline, 8 parts of tranexamic acid, 9 parts of arbutin and 12 parts of glabridin, wherein the sodium hyaluronate A is a product crosslinked by divinyl sulfone, and the crosslinking dissociation ratio of the sodium hyaluronate A is 71% to 29%; the raw material B comprises 130 parts of 120-130 ten thousand molecular weight sodium hyaluronate, 16 parts of tranexamic acid, 15 parts of nicotinamide, 22 parts of glutathione, 12 parts of retinol and 7 parts of salicylic acid, wherein the sodium hyaluronate B is a product crosslinked by butanediol glycidyl ether, and the crosslinking free ratio is 84% -16%.
Efficacy assessment
The evaluation method comprises the following steps: the efficacy of the dissolvable microneedle patch was evaluated by observing the change of the front and back of five groups of subjects using the test samples, the first group of subjects using the dissolvable microneedle patch of example 1 of the present invention, the fourth group of subjects using the dissolvable microneedle patch of example 2 of the present invention, the first group of subjects having dry eyes and forehead (as shown in the left part of fig. 3), the second group of subjects having a lot of pockmarks and closed acne (as shown in the left part of fig. 4), the third group of subjects having a lot of melanin and freckles deposited thereon (as shown in the left part of fig. 5), the fourth group of subjects using both the dissolvable microneedle patch of example 1 of the present invention (left use of cheek) and the dissolvable microneedle patch existing on the market (right cheek using acropas/espira patch), and the fifth group of subjects having a lot of pockmarks (as shown in the left part of fig. 7). Before the soluble microneedle patch is used, the face of a subject is cleaned and disinfected, then the soluble microneedle patch is taken out and placed on a tested part of the subject in a lying state, a patch of the soluble microneedle patch is slowly and uniformly pressed to enable a needle body to enter the skin, the soluble microneedle patch is applied to the tested part, the patch is slightly removed after two hours, the face is cleaned by only adopting facial cleanser every day in the later tested period (totally 24 weeks), an externally-applied moisturizing mask can be used without using any cosmetic product, and the subject is subjected to return visit and skin observation every two weeks. After the test, the face and cheek of the fourth group of subjects are subjected to optical projection scanning, and the image condition of the skin surface is observed.
And (4) evaluation results: after the first group of subjects used the dissolvable microneedles of the present invention for eight weeks, their eyes and forehead were full, elastic and shiny as shown in the right part of fig. 3; after the second group of subjects used the dissolvable microneedle patch of the present invention for week 4, as shown in the right part of fig. 4, the cheeks were full and elastic, and most of the pox had been reduced or even disappeared; after 16 weeks using the dissolvable microneedle patch of the present invention, the third group of subjects had full and elastic cheeks, freckles disappeared and no melanin deposition, as shown in the right part of fig. 5; after 24 weeks using the dissolvable microneedle patch of the present invention, the face cheek surface of the fourth group of subjects had almost no problem of local skin sagging as shown in the right part of fig. 6, while the face cheek surface after using the existing dissolvable microneedle patch had significant sagging (dark gray and black areas in the left half of the figure); after 12 weeks of use of the dissolvable microneedles of the present invention in the fifth group of subjects, most of the pockmarks on the cheek surface (initially smaller pockmarks) were repaired and initially larger pockmarks were significantly improved, as shown in the right part of fig. 7. Furthermore, each group of subjects presented neither allergic reactions nor inflammation and pain during the test period, depending on the subject feedback.
By adopting the soluble microneedle patch provided by the invention, the facial beauty duration of a user can be as long as half a year or more, and the problem of local skin concavity in the middle and later stages after microneedle beauty is almost avoided. The soluble microneedle patch provided by the invention has multiple skin care effects, is good in beautifying effect, can enable skin to be more elastic and glossy, can prevent skin moisture loss, moisturize and preserve water, can also whiten skin, resist oxidation and aging, resist sunscreen, allergy and wrinkle, has an acne generation prevention effect, and particularly has remarkable effects on removing freckles and acnes and improving facial melanin deposition.
In addition, on the basis of the prior art, in order to shorten the microneedle cosmetic time, the soluble microneedle patch can also be prepared into an active separation type soluble microneedle patch, so that the needle body and the patch can be quickly separated.
For solutions within the essential scope of the invention, it also comprises:
the whitening component includes, but is not limited to, hydroquinone (hydroquinone), azelaic acid, licorice extract, soybean extract, ferulic acid, glycolic acid, phenethyl resorcinol, kojic acid, ellagic acid, resveratrol, astaxanthin, lycopene;
said antiallergic component includes but is not limited to dipotassium glycyrrhizinate, bisabolol, aloe extract, chamomile extract, avenanthramide, paeonol, menthyl lactate, lactobacillus/soybean milk fermentation product filtrate;
the anti-aging ingredient includes but is not limited to coenzyme Q10 (ubiquinone), retinol, VC, VE, soy isoflavones, carnosine, centella asiatica, caffeine, ergothioneine, escin, green tea extract, palmitoyl pentapeptide-4, acetyl hexapeptide-8, acetyl tetrapeptide-5, oligopeptide-1;
the acne-removing components include, but are not limited to, azelaic acid, salicylic acid, mandelic acid, pyridoxine, tea tree essential oil, matrine, Saviae Miltiorrhizae radix extract, benzoyl peroxide, fruit acid, glycolic acid, citric acid, white willow bark extract, radix rehmanniae extract, Scutellariae radix extract, alternanthera leaf oil mangrove bark extract, cortex Magnolia officinalis extract, and pericarpium Granati extract.
Claims (6)
1. The utility model provides a soluble micropin subsides, includes the paster and sets up at the positive soluble needle body of paster, and soluble needle body is the segment structure, its characterized in that: the tail section needle body close to the patch is prepared from the following raw material A in parts by weight, and the first section needle body far away from the patch is prepared from the following raw material B in parts by weight; the raw material A comprises: 20-40 parts of 5-20 ten thousand molecular weight sodium hyaluronate A, 10-15 parts of a viscous mixture, 22-35 parts of palmitoyl glycine, 10-50 parts of keratin, 15-18 parts of retinol and 11-13 parts of tricin, wherein the sodium hyaluronate A is a product crosslinked by divinyl sulfone, and the crosslinking dissociation ratio of the sodium hyaluronate A is 71% to 29%; the raw material B comprises: 50-80 parts of 120-sodium hyaluronate B with the molecular weight of 130 ten thousand, 13-16 parts of whitening component, 7-15 parts of antiallergic component, 18-22 parts of antioxidant component, 8-12 parts of anti-aging component and 4-7 parts of acne-removing component, wherein the sodium hyaluronate B is a product crosslinked by butanediol glycidyl ether, and the crosslinking dissociation ratio is 84% to 16%.
2. The dissolvable microneedle patch according to claim 1, wherein: the soluble needle body is of a two-section structure, and the length of the tail section needle body is 1/4-1/3 of the total length of the soluble needle body.
3. The dissolvable microneedle patch according to claim 2, wherein: the first section needle body and the tail section needle body of the soluble needle body are mutually embedded and connected.
4. The dissolvable microneedle patch according to claim 1, 2, or 3, wherein: the raw material A also comprises: 7-8 parts of tranexamic acid, 5-7 parts of vitamin C, 5-7 parts of vitamin E, 6-9 parts of arbutin and 10-12 parts of Glassy liquorice.
5. The dissolvable microneedle patch according to claim 4, wherein: the raw material B also comprises: 14-17 parts of polyvinylpyrrolidone and 4-9 parts of collagen.
6. The dissolvable microneedle patch according to claim 5, wherein: the raw material A consists of 28-30 parts of sodium hyaluronate A with the molecular weight of 5-20 ten thousand, 12 parts of a viscous mixture, 25 parts of palmitoyl glycine, 30 parts of keratin, 15 parts of retinol, 11 parts of minocycline, 7 parts of tranexamic acid, 6 parts of vitamin C, 6 parts of vitamin E, 8 parts of arbutin and 11 parts of Glassy sorrel; the raw material B comprises 65 parts of 120-130 ten thousand molecular weight sodium hyaluronate B, 15 parts of tranexamic acid, 13 parts of nicotinamide, 21 parts of glutathione, 10 parts of retinol, 6 parts of salicylic acid, 6 parts of vitamin C, 14 parts of polyvinylpyrrolidone and 7 parts of collagen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010367191.0A CN111494237A (en) | 2020-04-30 | 2020-04-30 | Soluble micro-needle patch |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010367191.0A CN111494237A (en) | 2020-04-30 | 2020-04-30 | Soluble micro-needle patch |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111494237A true CN111494237A (en) | 2020-08-07 |
Family
ID=71848763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010367191.0A Pending CN111494237A (en) | 2020-04-30 | 2020-04-30 | Soluble micro-needle patch |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111494237A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111920699A (en) * | 2020-09-14 | 2020-11-13 | 广州新济薇娜生物科技有限公司 | Whitening and freckle-removing composition, whitening and freckle-removing soluble microneedle patch and preparation method thereof |
| CN112426386A (en) * | 2020-12-04 | 2021-03-02 | 天津尚美化妆品有限公司 | Oil-control acne-removing efficacy composition and gel |
| CN112641656A (en) * | 2020-12-30 | 2021-04-13 | 宇肽生物(东莞)有限公司 | Polypeptide microneedle and preparation method thereof |
| CN113827509A (en) * | 2021-10-22 | 2021-12-24 | 广东润和生物科技有限公司 | Coenzyme Q10 eye cream and preparation method thereof |
| CN113876618A (en) * | 2021-10-29 | 2022-01-04 | 湖北省麦诗特生物科技有限公司 | Micro-needle film composition for whitening skin, resisting oxidation and dissolving and beautifying skin and preparation method thereof |
| CN114028264A (en) * | 2021-11-26 | 2022-02-11 | 广州贝奥吉因生物科技股份有限公司 | Microneedle patch for acne removal and repair and preparation method and application thereof |
| CN115068385A (en) * | 2022-07-11 | 2022-09-20 | 广州市韵柯莱化妆品科技有限公司 | Whitening essence and preparation method thereof |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104069585A (en) * | 2014-07-03 | 2014-10-01 | 游学秋 | Separable microneedle system and manufacturing method thereof |
| US20150018755A1 (en) * | 2013-07-12 | 2015-01-15 | National Cheng Kung University | Substance delivery device and substance delivery method using the same |
| CN104707241A (en) * | 2015-03-25 | 2015-06-17 | 北京化工大学 | Two-stage-type micro-needle array and preparation method thereof |
| CN204684441U (en) * | 2015-05-05 | 2015-10-07 | 陈彦彪 | A kind of solvable micropin |
| CN105411997A (en) * | 2015-12-30 | 2016-03-23 | 李媚 | Degradable microstructure body and preparation method thereof |
| CN105596287A (en) * | 2016-02-04 | 2016-05-25 | 广州新济药业科技有限公司 | Active separation-type soluble microneedle and preparation method thereof |
| CN107050635A (en) * | 2016-12-30 | 2017-08-18 | 向卓林 | A kind of soluble micropin of segmented, microneedle array and preparation method thereof |
| CN108379095A (en) * | 2018-05-24 | 2018-08-10 | 优微（珠海）生物科技有限公司 | A kind of solubility microneedle patch and preparation method thereof |
| CN108392729A (en) * | 2018-04-20 | 2018-08-14 | 威海迈尼生物科技有限公司 | A kind of cross-linked-hyaluronic acid micropin of grafting drug |
| CN110870943A (en) * | 2018-08-31 | 2020-03-10 | 中科微针（北京）科技有限公司 | Implantable two-section type microneedle patch and preparation method thereof |
-
2020
- 2020-04-30 CN CN202010367191.0A patent/CN111494237A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150018755A1 (en) * | 2013-07-12 | 2015-01-15 | National Cheng Kung University | Substance delivery device and substance delivery method using the same |
| CN104069585A (en) * | 2014-07-03 | 2014-10-01 | 游学秋 | Separable microneedle system and manufacturing method thereof |
| CN104707241A (en) * | 2015-03-25 | 2015-06-17 | 北京化工大学 | Two-stage-type micro-needle array and preparation method thereof |
| CN204684441U (en) * | 2015-05-05 | 2015-10-07 | 陈彦彪 | A kind of solvable micropin |
| CN105411997A (en) * | 2015-12-30 | 2016-03-23 | 李媚 | Degradable microstructure body and preparation method thereof |
| CN105596287A (en) * | 2016-02-04 | 2016-05-25 | 广州新济药业科技有限公司 | Active separation-type soluble microneedle and preparation method thereof |
| CN107050635A (en) * | 2016-12-30 | 2017-08-18 | 向卓林 | A kind of soluble micropin of segmented, microneedle array and preparation method thereof |
| CN108392729A (en) * | 2018-04-20 | 2018-08-14 | 威海迈尼生物科技有限公司 | A kind of cross-linked-hyaluronic acid micropin of grafting drug |
| CN108379095A (en) * | 2018-05-24 | 2018-08-10 | 优微（珠海）生物科技有限公司 | A kind of solubility microneedle patch and preparation method thereof |
| CN110870943A (en) * | 2018-08-31 | 2020-03-10 | 中科微针（北京）科技有限公司 | Implantable two-section type microneedle patch and preparation method thereof |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111920699A (en) * | 2020-09-14 | 2020-11-13 | 广州新济薇娜生物科技有限公司 | Whitening and freckle-removing composition, whitening and freckle-removing soluble microneedle patch and preparation method thereof |
| CN111920699B (en) * | 2020-09-14 | 2022-10-04 | 广州新济薇娜生物科技有限公司 | Whitening and freckle-removing composition, whitening and freckle-removing soluble microneedle patch and preparation method thereof |
| CN112426386A (en) * | 2020-12-04 | 2021-03-02 | 天津尚美化妆品有限公司 | Oil-control acne-removing efficacy composition and gel |
| CN112641656A (en) * | 2020-12-30 | 2021-04-13 | 宇肽生物(东莞)有限公司 | Polypeptide microneedle and preparation method thereof |
| CN113827509A (en) * | 2021-10-22 | 2021-12-24 | 广东润和生物科技有限公司 | Coenzyme Q10 eye cream and preparation method thereof |
| CN113827509B (en) * | 2021-10-22 | 2023-07-04 | 广东润和生物科技有限公司 | Coenzyme Q10 eye cream and preparation method thereof |
| CN113876618A (en) * | 2021-10-29 | 2022-01-04 | 湖北省麦诗特生物科技有限公司 | Micro-needle film composition for whitening skin, resisting oxidation and dissolving and beautifying skin and preparation method thereof |
| CN113876618B (en) * | 2021-10-29 | 2023-09-22 | 湖北省麦诗特生物科技有限公司 | Skin whitening, antioxidation soluble beauty microneedle patch composition and preparation method thereof |
| CN114028264A (en) * | 2021-11-26 | 2022-02-11 | 广州贝奥吉因生物科技股份有限公司 | Microneedle patch for acne removal and repair and preparation method and application thereof |
| CN115068385A (en) * | 2022-07-11 | 2022-09-20 | 广州市韵柯莱化妆品科技有限公司 | Whitening essence and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111494237A (en) | Soluble micro-needle patch | |
| CN109937031B (en) | Kangaroo claw extract for cosmetic use | |
| US8460721B2 (en) | Active ingredient that stimulates the proliferation and/or activity of fibroblasts | |
| KR102265730B1 (en) | cosmetic composition for skin wrinkle improvement and whitening facial skin | |
| US20200254044A1 (en) | Composition comprising plant-derived extracellular vesicles | |
| BR102017026285A2 (en) | topical composition containing glycerin and yeast extract | |
| CN104146879A (en) | Anti-aging double-face mask and preparation methods of mask essence liquid | |
| CN113576975A (en) | Easily-absorbed anti-aging composition and preparation method and application thereof | |
| CN112826847A (en) | Microneedle patch for removing acne and removing acne marks and preparation method thereof | |
| CN106999378B (en) | Dermatological kit comprising a composition based on hibiscus flower and brischt fruit oil | |
| JP2010241762A (en) | Cosmetic | |
| KR102368903B1 (en) | A composition for increasing the thickness of eyelashes, eyebrows and hair and promoting growth | |
| KR101254330B1 (en) | Cosmetic composition for removal the wrinkles at the corners of one´s eyes | |
| CN107669617A (en) | The tender skin cosmetics of natural anti-wrinkle | |
| EP3052199B1 (en) | Use of an oily composition comprising an hemerocallis extract for improving firmness of the skin | |
| CN112107527A (en) | Anti-hair loss essence and preparation method thereof | |
| JP7289833B2 (en) | Cosmetic use of plant Elephant extract (Phytelephas sp.) | |
| KR20160017891A (en) | Composition for protecting skin with antioxidant activity comprising egf and placenta | |
| KR102285828B1 (en) | Cosmetic composition containing skin strengthening composition and method for producing same | |
| CN218943909U (en) | Antioxidant anti-aging soluble beauty micro-needle patch | |
| EP4108094A1 (en) | Coffee melanoidin nanoparticles and nanofibers | |
| TWI809596B (en) | Ferment from structured water medium and cosmetic composition comprising the same | |
| KR20210152372A (en) | Adipocyte differentiation inhibitor and composition comprising the same | |
| CN115666501A (en) | Skin care product with protein matrix | |
| CN117940103A (en) | Topical composition for combating fine lines and wrinkles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200807 |
|
| RJ01 | Rejection of invention patent application after publication |